{"id":"discontinuation-of-oxytocin-administration","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxytocin is a naturally occurring hormone used clinically to induce or augment labor and to control postpartum hemorrhage. Discontinuing its administration allows the exogenous stimulus to uterine smooth muscle contraction to cease, permitting the uterus to return to baseline contractility. This is a procedural intervention rather than a pharmacological agent with a specific molecular mechanism.","oneSentence":"Discontinuation of oxytocin administration removes the exogenous hormone that stimulates uterine contractions and milk letdown.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:49.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Management of labor induction or augmentation when continuation is no longer clinically indicated"},{"name":"Reduction of postpartum hemorrhage risk when oxytocin infusion is no longer needed"}]},"trialDetails":[{"nctId":"NCT03991091","phase":"PHASE4","title":"Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-01-17","conditions":"Neonatal Morbidity","enrollment":2459},{"nctId":"NCT04303702","phase":"NA","title":"The Role of Oxytocin in the Second Stage of Labor","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2022-07-01","conditions":"Labor Complication","enrollment":400},{"nctId":"NCT06403982","phase":"NA","title":"The Influence of Oxytocin on Intrapartum Fetal Well-being and Delivery Outcomes in Patients Receiving Epidural Analgesia","status":"ENROLLING_BY_INVITATION","sponsor":"Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland","startDate":"2024-05-06","conditions":"Uterine Contraction, Oxytocin, Labor Progress","enrollment":200},{"nctId":"NCT02553226","phase":"PHASE4","title":"Continued Versus Discontinued Oxytocin Stimulation of Labour","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2016-04","conditions":"Adverse Reaction to Oxytocin","enrollment":1200},{"nctId":"NCT02566005","phase":"NA","title":"A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2015-09","conditions":"Pregnancy","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"discontinuation of oxytocin administration","genericName":"discontinuation of oxytocin administration","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Discontinuation of oxytocin administration removes the exogenous hormone that stimulates uterine contractions and milk letdown. Used for Management of labor induction or augmentation when continuation is no longer clinically indicated, Reduction of postpartum hemorrhage risk when oxytocin infusion is no longer needed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}